One of yesterday’s big late-breaking trial from AHA’s annual meeting was the JUPITER trial (Rosuvastatin in the Prevention of Cardiovascular Events Among 17,802 Men and Women with Elevated Levels of C-Reactive Protein). The trial has fascinating findings. Up to now, there has been an inconsistent measuring of C-Reactive Protein in patients because it was unclear if it was helpful or not. JUPITER indicates that even if a patient is otherwise relatively healthy, if they have an elevated CRP, they should be put on a statin. With the release of this trial, physicians need to begin measuring CRP again and treat it with statins. This is going have an immediate impact of practice patterns for cardiologists. Not to mention, it goes to show the importance of clinical evidence in guiding decision making. I encourage you to read more about the study.